lpath inc-class a (LPTN) Key Developments
Lpath Reports Results for iSONEP™ in Patients with Wet Age-related Macular Degeneration
May 20 15
Lpath Inc. announced that its multicenter, Phase 2 "Nexus" clinical trial evaluating iSONEP™ in patients with wet age-related macular degeneration (wet AMD) did not meet its primary or key secondary endpoints. Wet AMD patients who had not responded adequately to existing anti-vascular endothelial growth factor (VEGF) therapies including Lucentis®, Avastin® and Eylea® did not show any statistically significant improvement in visual acuity when treated with iSONEP as an adjunctive or monotherapy. Nexus is a prospective, randomized, double-masked, positive control, Phase 2 clinical trial conducted in the U.S. that enrolled 158 patients with wet AMD. All enrolled patients had been subresponsive to treatment with anti-VEGF drugs, and had received at least three previous injections of an anti-VEGF drug. Nexus study patients each received four intravitreal injections over the 90 day dosing period. There were approximately 39 patients in each of the four treatment arms. The pre-specified primary endpoint of the study was mean change in best corrected visual acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) from Day 0 to Day 120. At day 120, patients who received intravitreal injections of (i) 4.0 mg iSONEP alone lost a mean of 3.17 letters on the ETDRS, (ii) a combination of 0.5 mg iSONEP and anti-VEGF therapy gained a mean of 4.22 letters, (iii) a combination of 4.0 mg iSONEP and anti-VEGF therapy gained a mean of 3.63 letters, and (iv) an anti-VEGF therapy alone gained a mean of 4.34 letters. Full study results will be presented during the Retina Subspecialty Days in conjunction with the American Academy of Ophthalmology in Las Vegas, Nevada in November 2015.
Lpath Inc., Annual General Meeting, Jun 16, 2015
Apr 27 15
Lpath Inc., Annual General Meeting, Jun 16, 2015., at 09:00 Pacific Standard Time. Location: 4025 Sorrento Valley Blvd. Agenda: To elect five directors to hold office until the next annual meeting and until their respective successors are elected and qualified; to ratify the appointment of Moss Adams LLP as independent registered public accounting firm for the fiscal year ending December 31, 2015; to hold a non-binding advisory vote on the compensation of named executive officers; to approve an amendment to amended and restated 2005 equity incentive plan which, among other changes described in Proxy Statement, increases the number of shares of common stock issuable under the plan by 1,700,000 shares; and to transact such other business as may properly be brought before the meeting or any adjournment or postponement thereof.
Lpath Inc. - Shareholder/Analyst Call
Mar 23 15
To update investors on the progress of Lpath's programs
Lpath Inc. Submits Investigational New Drug Application for Lpathomab for Neuropathic Pain
Feb 2 15
Lpath Inc. announced that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to conduct a Phase 1 study of Lpathomab™ for the treatment of neuropathic pain. The primary objective of the study is to evaluate the safety and tolerability of Lpathomab in subjects that are experiencing neuropathic pain. Lpath plans to begin enrolling patients once the FDA's IND review period is complete and the study has been approved by the trial sites' investigational review boards. Lpathomab is an internally discovered, first-in-class antibody targeting Lysophosphatidic Acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain. Lpath's preclinical studies showed strong in vivo results with Lpathomab in several different pain models, which suggest that LPA may be an attractive target across a variety of chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain and pain associated with lumbosacral radiculopathy.
Lpath Inc. - Special Call
Dec 2 14
To update on the progress of the Nexus trial as well as other programs